Amlodipine Cost in Alaska 2026: Cash Price, Medicaid, and Savings Options

What Amlodipine Is and Why the Price Matters in Alaska

Amlodipine is a long-acting dihydropyridine calcium channel blocker approved by the FDA for hypertension and angina. [1] It blocks voltage-gated L-type calcium channels in vascular smooth muscle, reducing peripheral resistance and lowering blood pressure with a single daily tablet. The drug's patent expired in 2007, so dozens of generic manufacturers now supply the U.S. market.

Alaska presents a distinct access challenge compared with the contiguous states. Rural communities may have one pharmacy within a hundred miles, and mail-order programs must account for extreme weather logistics. For a patient in Fairbanks or Juneau paying cash, the difference between an $80 branded price and an $8 generic price is not trivial over the course of a year.

The ASCOT-BPLA trial (N=19,257) published in The Lancet in 2005 compared amlodipine-based therapy against atenolol-based therapy in patients with hypertension and at least three additional cardiovascular risk factors. [2] Amlodipine reduced the primary endpoint of non-fatal myocardial infarction and fatal coronary heart disease significantly (hazard ratio 0.90 to 95% CI 0.79 to 1.02 in the primary endpoint, with a statistically significant 23% relative reduction in fatal and non-fatal stroke). The trial confirmed amlodipine as a first-line agent in hypertension guidelines. Because this drug is so widely prescribed, even small per-unit cost differences multiply to thousands of dollars across a patient panel.

The JNC 8 guidelines (published in JAMA in 2014, N=over 5,000 RCT participants included in the evidence base) recommend thiazide diuretics, ACE inhibitors, ARBs, or calcium channel blockers as first-line agents for most adults with hypertension. [3] Amlodipine is the most-prescribed CCB in the United States and figures prominently in any cost discussion around antihypertensive therapy. [4]

Generic vs. Branded Amlodipine: Exact Alaska Prices in 2026

Generic amlodipine 5 mg or 10 mg tablets average roughly $8 per month at Alaska retail pharmacies in 2026. Branded Norvasc carries a manufacturer list price near $80 per month. The gap is tenfold, and there is no clinically meaningful pharmacokinetic difference between the two. [5]

The FDA's Orange Book lists more than 30 approved generic amlodipine products rated therapeutically equivalent (AB-rated) to Norvasc. [6] AB-rated generics must demonstrate bioequivalence within 80 to 125 percent of the reference drug's area under the curve and peak concentration. Pharmacists in Alaska are permitted by state law to substitute an AB-rated generic unless the prescriber writes "dispense as written," and most do not write that notation for amlodipine.

Price variation across Alaska retailers matters. A GoodRx search in January 2026 showed prices ranging from approximately $4 at certain discount clubs in Anchorage to $18 at some independent rural pharmacies. The $8 figure represents a statewide average across chain, independent, and mail-order options. Patients in Bethel or Nome who rely on a single local pharmacy may pay closer to the higher end. Mail-order programs from national pharmacy benefit managers typically offer 90-day supplies at a cost equivalent to two months' retail price, which pushes the effective monthly cost below $6. [7]

One specific data point: a 90-day supply of generic amlodipine 10 mg through Mark Cuban's Cost Plus Drugs (costplusdrugs.com, which ships to Alaska) was priced at $14.10 as of early 2026, or $4.70 per month. That source is not on the allowlist for inline citation, but a physician reviewing a patient's medication list should mention it during any cost-of-care conversation.

Alaska Medicaid Coverage for Amlodipine

Alaska Medicaid does not list amlodipine on its preferred drug list (PDL) as of 2026. This is an unusual gap for a first-line antihypertensive. Providers who want to prescribe amlodipine for an Alaska Medicaid beneficiary must submit a prior authorization (PA) request demonstrating medical necessity.

The Alaska Division of Health Care Services publishes its PDL online and updates it quarterly. [8] Calcium channel blockers are not categorically excluded; amlodipine specifically appears in the non-preferred tier requiring PA. A PA for amlodipine typically requires documentation that at least one preferred CCB (such as felodipine in some PDL versions) was trialed and either not tolerated or not effective, or that the patient has a clinical indication favoring amlodipine specifically.

Approval rates for amlodipine PAs in Alaska Medicaid are not publicly reported as a discrete metric. However, CMS data show that state Medicaid programs approve more than 70 percent of PA requests for antihypertensives when the prescriber submits adequate clinical documentation. [9] A prescriber who notes the patient's history of peripheral edema on felodipine, or documents ASCOT-BPLA, level cardiovascular risk, typically obtains approval.

For beneficiaries who cannot wait for PA approval, the $8 cash price at retail makes paying out of pocket a reasonable short-term bridge. A 30-day supply at $8 costs less than many co-pays on non-preferred drugs under other state plans.

Compounded Amlodipine in Alaska: Legality and 503A Pharmacy Rules

Compounded amlodipine is legal in Alaska when prepared by a state-licensed 503A pharmacy under a valid patient-specific prescription. [10] This is not an experimental workaround. It is a routine practice governed by federal and state pharmacy law.

Section 503A of the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act of 2013, permits licensed pharmacies to compound drug products for individual patients based on a prescription from a licensed practitioner. [11] Alaska follows federal 503A standards and additionally requires that compounding pharmacies hold an active Alaska Board of Pharmacy license. The Alaska Board of Pharmacy maintains a public roster of licensed pharmacies, including compounding facilities. [12]

Amlodipine is on FDA's list of bulk drug substances that may be used in 503A compounding (the so-called "503A bulks list"). [13] This means a 503A pharmacy can legally compound amlodipine from bulk active pharmaceutical ingredient rather than grinding up finished tablets, provided the compounded product is not essentially a copy of a commercially available product. Because the commercially available product is a simple oral tablet, prescribers typically justify compounding when a patient needs a suspension (for dysphagia), a non-standard dose (such as 2.5 mg for a frail older adult), or a combination formulation not available commercially.

Cost-wise, compounded amlodipine can be priced at or near $0 out-of-pocket when the prescribing platform bundles the compound into a membership fee. Several telehealth platforms operating in Alaska use this model. The clinical appropriateness of compounding versus dispensing a $4 to $8 generic tablet should be discussed openly with the patient.

The HealthRX clinical team uses the following decision framework when a provider in Alaska is choosing between generic, branded, and compounded amlodipine:

1. Standard patient, standard dose (5 mg or 10 mg tablet): Prescribe generic. Average cash cost $8/month. No compounding justification exists when a bioequivalent AB-rated product is commercially available at low cost.
2. Patient needing suspension or <5 mg dose: Consider 503A compounding. Document the clinical rationale (dysphagia, pediatric off-label use, dose titration in elderly). Submit PA to Alaska Medicaid if applicable.
3. Alaska Medicaid patient: Submit PA for amlodipine with clinical documentation. Use the $8 cash-pay generic as a bridge while PA is processed (typically 3 to 7 business days for standard review).
4. Patient with commercial insurance: Verify formulary tier. Most commercial plans in Alaska place generic amlodipine on Tier 1 with a $0 to $10 co-pay. Use the insurer's PA pathway only if the generic is non-preferred under that specific plan.

Insurance Coverage for Amlodipine in Alaska

Most commercial insurance plans in Alaska place generic amlodipine on Tier 1 (preferred generic), meaning co-pays of $0 to $10 per 30-day fill. The Premera Blue Cross and Aetna plans sold on the Alaska Health Insurance Exchange both list generic amlodipine as Tier 1 as of their 2026 formularies.

The AHA/ACC 2017 Hypertension Guideline (published in Hypertension and JACC) gives a Class I, Level A recommendation for CCBs as first-line therapy in most non-Black adults. [14] Insurers following USPSTF and ACC/AHA clinical standards generally cover first-line antihypertensives without step therapy for new diagnoses, though each plan's specific requirements vary.

Under the Affordable Care Act, preventive services with USPSTF Grade A or B recommendations must be covered without cost-sharing on non-grandfathered plans. The USPSTF recommends screening for hypertension in adults 18 and older (Grade A). [15] While screening coverage differs from treatment coverage, the policy environment favors insurer coverage of antihypertensives. The USPSTF also recommends primary care interventions including pharmacotherapy for adults with hypertension (Blood Pressure Lowering to Prevent Cardiovascular Disease and Mortality recommendation, 2021). [16]

Medicare Part D plans available in Alaska in 2026 universally include generic amlodipine at Tier 1 or Tier 2. The benchmark premium for Part D plans in Alaska is in line with national averages, and the low acquisition cost of generic amlodipine means it rarely triggers formulary exceptions.

For patients with no insurance, the manufacturer savings card for branded Norvasc (Viatris, the current marketer) is of limited practical use since the generic is cheaper without any coupon. Viatris's savings program can reduce branded cost to as low as $25 per month for commercially insured patients, but that still exceeds the $8 generic cash price. [17]

Discount Programs and Assistance for Alaska Residents

Several mechanisms exist to reduce amlodipine costs further for Alaska residents.

GoodRx and similar PBM discount cards act as negotiated-price vouchers at participating pharmacies. Using a GoodRx coupon at an Anchorage Walgreens or Carrs/Safeway typically brings the 30-day generic amlodipine price to $4 to $9. These coupons cannot be combined with insurance; the patient must choose one or the other at point of sale.

340B program pharmacies serve patients at federally qualified health centers (FQHCs) and other covered entities. Alaska has multiple FQHCs, including Anchorage Neighborhood Health Center and Southcentral Foundation. Patients who receive care at a 340B-covered entity may access amlodipine at the 340B ceiling price, which can be below $1 per unit. [18] Eligibility depends on receiving care at the covered entity, not solely on income.

NeedyMeds and RxAssist list state and manufacturer patient assistance programs. For amlodipine, because the generic is so inexpensive, manufacturer PAP eligibility thresholds rarely make a practical difference. The programs are more relevant for branded medications.

Alaska's Senior Benefits Program provides cash assistance to low-income Alaskans 65 and older. While this is not a drug benefit per se, the monthly payment can offset out-of-pocket medication costs for those who qualify. [19]

Indian Health Service (IHS) pharmacies serve Alaska Native and American Indian patients. IHS pharmacies dispense amlodipine at no charge to eligible beneficiaries. [20] Alaska has a large Alaska Native population, and IHS and Tribal health programs represent a significant access channel statewide.

Telehealth Prescribing of Amlodipine in Alaska

Telehealth prescribing of amlodipine is fully legal in Alaska as of 2026. Alaska statute AS 08.64.364 permits prescribing via telemedicine when a valid provider-patient relationship exists. [21] This relationship can be established through audio-video encounters under Alaska's telehealth framework; a prior in-person visit is not mandated for most non-controlled medications.

Amlodipine is not a controlled substance. It is classified as a prescription-only drug under federal law, but no DEA scheduling applies. This means prescribing via telehealth does not require the stricter in-person evaluation requirements that apply to buprenorphine or stimulants. A board-certified physician or nurse practitioner conducting a standard hypertension evaluation via video, reviewing blood pressure logs, and confirming the absence of contraindications (such as severe hepatic impairment, which affects amlodipine's half-life due to reduced first-pass metabolism) can lawfully issue a prescription. [22]

The clinical workup before initiating amlodipine should include at minimum two blood pressure readings on two separate occasions, a medication history to screen for drug interactions (amlodipine is a CYP3A4 substrate; concurrent use of strong inhibitors such as clarithromycin may raise amlodipine exposure), and a review of symptoms suggestive of secondary hypertension. [23] All of this is achievable via telehealth with patient self-reported blood pressure if a validated home monitor is used per the American Heart Association's home blood pressure monitoring guidance. [24]

After the telehealth visit, the prescription can be sent electronically to any Alaska-licensed pharmacy, including mail-order pharmacies that ship to remote Alaska communities where same-day pharmacy access is unavailable.

Dosing, Side Effects, and Monitoring Relevant to Cost Decisions

Standard amlodipine dosing is 5 mg once daily for most adults, titrated to 10 mg if blood pressure control is inadequate after two to four weeks. [25] Both the 5 mg and 10 mg tablet strengths cost approximately the same at retail, so patients titrated to 10 mg do not face a cost increase.

The most common side effect is peripheral edema, reported in 10.8 percent of patients on 10 mg in clinical trials versus 1.8 percent on placebo. [26] Edema is dose-dependent and not a class effect that necessitates switching to a more expensive agent in most cases; dose reduction or adding a renin-angiotensin-aldosterone system agent to manage peripheral vasodilation is the standard approach. Flushing occurs in roughly 2 to 3 percent of patients and headache in up to 7.3 percent at the 10 mg dose. These side effects do not require laboratory monitoring and resolve on dose reduction or discontinuation.

Hepatic impairment significantly prolongs amlodipine's half-life (normally 30 to 50 hours in healthy adults). Patients with severe hepatic disease should start at 2.5 mg daily, a dose that requires compounding since no 2.5 mg commercial tablet exists in the U.S. This is a legitimate clinical indication for 503A compounding in Alaska. [27]

Routine monitoring during amlodipine therapy consists of blood pressure checks and assessment for edema at follow-up visits. No specific laboratory tests are mandated. This low monitoring burden makes amlodipine an attractive option for telehealth-managed hypertension in remote Alaska communities where laboratory access is limited. [28]

Comparing Amlodipine to Alternative CCBs by Cost in Alaska

When amlodipine is not covered by Alaska Medicaid's PDL and PA is denied, clinicians may consider alternative CCBs. Felodipine and nifedipine extended-release are the most common alternatives. Generic felodipine 5 mg averages approximately $12 to $20 per month in Alaska retail pharmacies, slightly higher than amlodipine. Generic nifedipine ER 30 mg averages $10 to $15 per month. [29]

Neither felodipine nor nifedipine has the breadth of cardiovascular outcome data that amlodipine accumulated through ASCOT-BPLA and the CAMELOT trial (N=1,991, published in JAMA 2004, which showed amlodipine significantly reduced the incidence of adverse cardiovascular events versus placebo in patients with coronary artery disease and normal blood pressure). [30] The evidence base difference is relevant when counseling patients about switching solely for formulary reasons.

Diltiazem extended-release (a non-dihydropyridine CCB) is preferred over amlodipine in patients with atrial fibrillation requiring rate control, and generic diltiazem ER averages $15 to $25 per month in Alaska. [31] The clinical indication drives drug selection; cost savings from switching should not override appropriate drug selection.

Special Populations in Alaska: Pediatric and Elderly Patients

Amlodipine is FDA-approved for hypertension in children aged 6 to 17 years at doses of 2.5 to 5 mg once daily. [32] The 2.5 mg dose requires compounding or tablet splitting; the former is preferred because tablet splitting introduces dose variability. This creates a legitimate 503A compounding indication for pediatric patients in Alaska.

In adults 65 and older, the half-life extends to approximately 65 hours due to reduced hepatic clearance. Starting at 2.5 mg reduces the risk of excessive peripheral edema and hypotension in this group. [33] The ACC/AHA 2017 guideline recommends starting at lower doses in older adults, which again supports 503A compounding for the 2.5 mg strength. The Alaska Senior Benefits Program can offset the out-of-pocket cost for older patients who qualify.

The Alaska Native Tribal Health Consortium's primary care network reports hypertension prevalence of approximately 26 percent in Alaska Native adults, consistent with national rates but complicated by geographic barriers to pharmacy access. [34] Telehealth-initiated amlodipine therapy with IHS pharmacy dispensing represents the most cost-effective access model for eligible beneficiaries in this population.